BioSpace News Archive

ANGLE plc is pleased to announce its participation at the American Association for Cancer Research Annual Meeting, San Diego, US between 5 to 10 April 2024.

ViroCell Biologics announces that John W. Hadden II, Chief Executive Officer, will be presenting at the annual Cell & Gene Meeting on the Med to be held April 9-11 in Rome, Italy.

D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its closing of Series A+ financing round led by Medicxi, a leading European life sciences investment firm.

Calliditas Therapeutics AB announced that the Company has received a Notice of Allowance from the United States Patent and Trademark Office for patent application no. 16/760,910 entitled “Use of NOX Inhibitors for Treatment of Cancer”.

Ocugen, Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug amendment to initiate a Phase 3 clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa.

Eyenovia, Inc., a commercial-stage ophthalmic company, announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia and initiated a process to explore strategic alternatives to maximize shareholder value.

Bio-Techne Corporation announced that Advanced Cell Diagnostics, part of Bio-Techne’s Spatial Biology Division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope™ ISH technology.

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that Ayana Pharma Ltd. signed a five-year Master Service Agreement (MSA) with the Company’s CDMO business unit, Scinai Bioservices.

Syndax Pharmaceuticals today announced the presentation of positive data from the pivotal AUGMENT-101 trial in pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) treated with revumenib, a first-in-class menin inhibitor.

Domain Therapeutics announced its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean A. MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2024: This press release features multimedia.